Key points from article :
New research demonstrates use of fat-associated lymphoid clusters to expand niches for ectopic liver regeneration.
Paper published in Hepatology describes restoration of liver function.
"... resulted in the restoration of liver function and rescuing the animals from otherwise fatal liver disease” - Dr Eric Lagasse, CSO at LyGenesis.
Hepatocyte transplantation holds great promise as an alternative approach to whole-organ transplantation.
One donor organ could treat dozens of patients via outpatient endoscopic ultrasound for transplantation of its cell therapy, rather than major surgery.
LyGenesis’s technology is built on preclinical studies showing that lymph nodes can serve as sites for organogenesis.
The company is developing cell therapies for patients with end stage liver disease, Type 1 diabetes, end stage renal disease, single enzyme deficiencies and aging.
“We are excited about the potential to impact patients as LyGenesis commences its first clinical trial among patients with end stage liver disease" - Dr David Roblin, CEO of Juvenescence Therapeutics.
